ties and Exchange Commission ("SEC") on August 5, 2008, which may
be obtained for free at the SEC's website at
http://www.sec.gov. Although
we believe that the expectations reflected in our forward-looking
statements are reasonable, we do not know whether our expectations will
prove correct. All forward-looking statements included in this press
release are expressly qualified in their entirety by the foregoing
cautionary statements. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of today's date. We
do not undertake any obligation to update, amend or clarify these
forward-looking statements or the "Risk Factors" contained in our Quarterly
Report on Form 10-Q for the fiscal quarter ended June 28, 2008, whether as
a result of new information, future events or otherwise, except as may be
required under the applicable securities laws.
(1) Continuous Pulse Ox Impacts Early Detection of Physiological
Abnormalities in Post-Surgical Patients. George Blike, M.D., Jean Avery,
R.N., Melanie Mastanduno, R.N., Klaus Christoffersen, Ph.D., Susan McGrath,
Ph.D. Quality & Patient Safety, Dartmouth-Hitchcock Medical Center,
Lebanon, NH.
(2) Do Pulse CO-Oximeter Measures of SpMet and SpO2 Correlate with
Blood Gas CO-Oximetry in Neonates. Mitchell R. Goldstein, M.D., Daniel
Saesim, M.D., Mark Macknet, M.D., Martin Allard, M.D., Ricardo Peverini,
M.D. Neonatal Medicine, Loma Linda University Children's Hospital, Loma
Linda, California.
(3) Ability of Pleth Variability Index to Non Invasively Predict the
Hemodynamic Effects of PEEP. Olivier Desebbe, M.D., Cecile Boucau, R.D.,
Pascal Rosamel, M.D., Jean-Jacques Lehot, M.D., Ph.D., Maxime Cannesson,
M.D. Department of Anesthesiology, Louis Pradel Hospital, Lyon-Bron,
France.
(4) Pulse Oximeter Perfusion Index as a Predictor for the Effect of
llio-Inguinal Block. Aki Uemura, M.D., Ph.D., Masahiro Yagihara, M.D.,
'/>"/>
SOURCE Masimo Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound3.
Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States4.
The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma5.
PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials6.
Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio7.
ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials8.
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs9.
Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia10.
YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer11.
New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome